# Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

> **NCT00005842** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** tipifarnib

## Key facts

- **NCT ID:** NCT00005842
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2004-02
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005842, "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00005842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*